X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Stephen J. Ubl

Stephen J. Ubl Stephen J. Ubl is president and chief executive officer of PhRMA. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures.

Recent Posts

Congratulations to our 2022 Working for Cures Employee Champions

By Stephen J. Ubl  |    November 10, 2022
The Working for Cures Employee Champion Awards celebrate the real people in our industry who go above and beyond to advance science and support the work our industry does for patients.   Read More

PDUFA and BsUFA reauthorizations are wins for patients

By Stephen J. Ubl  |    October 5, 2022
America relies on the U.S. Food & Drug Administration (FDA) to keep pace with the scientific advancements happening every day in labs across the country. That’s why the recently enacted Prescription...   Read More

An open letter to Congress: Stand with patients and future cures

By Stephen J. Ubl  |    August 4, 2022
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read the letter here or below:   Read More

Copay assistance is a lifeline for patients. So why are insurers blocking it?

By Stephen J. Ubl  |    June 29, 2022
In today’s broken insurance system, patients too often pay more for a medicine than what their insurance company pays.   Read More

Biopharmaceutical researchers to discuss the value of R&D with Congress

By Stephen J. Ubl  |    June 9, 2022
Today, researchers from PhRMA member companies will meet virtually with members of Congress and Capitol Hill staff to discuss the importance of biopharmaceutical innovation in bringing new treatments...   Read More

A conversation with Barry Greene, CEO of Sage Therapeutics

By Stephen J. Ubl  |    May 4, 2022
Our industry continues working to build a more resilient, affordable and equitable health care system. As part of Mental Health Awareness Month, I recently had the opportunity to connect with PhRMA...   Read More

Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry

By Stephen J. Ubl  |    September 28, 2021
I am excited to join with Dr. Michael L. Lomax, President & CEO, UNCF; Dr. James Gillespie, President & Co-Founder, Center for Healthcare Innovation (CHI); and Dr. Chad Womack, Co-Founder and...   Read More

A global focus on ending the COVID-19 pandemic

By Stephen J. Ubl  |    September 22, 2021
Today, President Biden convened global leaders to confront the challenges around ending this pandemic. We stand with the president, all governments, organizations and sectors in a shared commitment...   Read More

America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

By Stephen J. Ubl  |    September 15, 2021
Today, PhRMA member companies made public an open letter to Capitol Hill to encourage Congress to abandon old partisan ideas on drug pricing and instead pursue policies that actually address what...   Read More

The future of the rebate rule: Will policymakers stand with patients?

By Stephen J. Ubl  |    August 2, 2021
Policymakers will soon decide whether to stand by new Medicare changes that will help lower costs for beneficiaries at the pharmacy counter or abandon these changes to fund government programs...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates